Claims for Patent: 11,559,523

Summary for Patent: 11,559,523

Title:	Compositions and methods for treating centrally mediated nausea and vomiting
Abstract:	Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
Inventor(s):	Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
Assignee:	Helsinn Healthcare SA
Application Number:	US17/075,757
Patent Claims:	1. A method of treating emesis in a patient in need thereof comprising orally administering to said patient a solid oral dosage form comprising a combination of a therapeutically effective amount of palonosetron or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of netupitant or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein said emesis is induced by cancer chemotherapy or radiotherapy. 3. The method of claim 1, wherein the emesis is induced by highly emetogenic or moderately emetogenic chemotherapy. 4. The method of claim 1, wherein said treating comprises preventing said emesis. 5. The method of claim 1, further comprising administering chemotherapy to said patient after said solid oral dosage form, wherein said solid oral dosage form is administered no more than two hours before said chemotherapy. 6. The method of claim 1, wherein said therapeutically effective amounts comprise from 100 to 300 mg of netupitant and 0.5 mg of palonosetron hydrochloride based on the weight of the free base. 7. The method of claim 1, wherein said therapeutically effective amounts comprise 300 mg of netupitant and 0.5 mg of palonosetron hydrochloride based on the weight of the free base. 8. A method of treating delayed-onset emesis in a patient in need thereof comprising orally administering to said patient a solid oral dosage form comprising a combination of a therapeutically effective amount of palonosetron or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of netupitant or a pharmaceutically acceptable salt thereof. 9. The method of claim 8, wherein said emesis is induced by cancer chemotherapy or radiotherapy. 10. The method of claim 8, wherein the emesis is induced by highly emetogenic or moderately emetogenic chemotherapy. 11. The method of claim 8, wherein said treating comprises preventing said emesis. 12. The method of claim 8, further comprising administering chemotherapy to said patient after said solid oral dosage form, wherein said solid oral dosage form is administered no more than two hours before said chemotherapy. 13. The method of claim 8, wherein said therapeutically effective amounts comprise from 100 to 300 mg of netupitant and 0.5 mg of palonosetron hydrochloride based on the weight of the free base. 14. The method of claim 8, wherein said therapeutically effective amounts comprise 300 mg of netupitant and 0.5 mg of palonosetron hydrochloride based on the weight of the free base. 15. An orally administered dosage form comprising a combination of a therapeutically effective amount of palonosetron or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of netupitant or a pharmaceutically acceptable salt thereof. 16. The dosage form of claim 15, wherein said therapeutically effective amounts are effective to treat emesis induced by cancer chemotherapy or radiotherapy. 17. The dosage form of claim 15, wherein said therapeutically effective amounts comprise from 100 to 300 mg of netupitant and 0.5 mg of palonosetron hydrochloride based on the weight of the free base. 18. The dosage form of claim 15, wherein said therapeutically effective amounts comprise 300 mg of netupitant and 0.5 mg of palonosetron hydrochloride based on the weight of the free base.